The content on this site is intended for healthcare professionals only
Advances in the treatment of lung cancer
Published: 7 Jun 2010
Views: 9269
Prof Rafael Rosell - University of Barcelona
Prof Rafael Rosell, speaking at the 2010 ELCC conference, talks about the importance of the ELCC 2010 conference and outlines the advances in lung cancer treatment that he has presented at this year's conference.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
- Targeted molecules
Related Videos
WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...
19 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
11 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
6 Oct 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuva...
Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute...
23 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
21 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Aug 2021
Predicting survival in NSCLC patients with poor performance status in resource-c...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
5 Aug 2021